Company / Working Capital
Viridian Therapeutics, Inc.\DE Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$823.5M
FY2025
5-year range
$186.5M / $823.5M
FY2021-FY2025
Trend
+19.3%
vs FY2024
Sector context
#48 of 213
Health Care
What the data says
Viridian Therapeutics, Inc.\DE's working capital of $824M is higher than 77% of companies in the Health Care sector (FY2025). Working Capital has increased for 6 consecutive years, from $20M in FY2019 to $824M in FY2025.
Based on SEC 10-K filings.
$824M in FY2025 with a 5-year CAGR of +47.3%. Top quartile in the Health Care sector.
Improved from $460M to $824M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +27.4%
- 5-Year CAGR
- +47.3%
- 10-Year CAGR
- -
Sector benchmark
-11.9% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's working capital has grown for 6 consecutive years.
- 5-year CAGR of +47.3%, indicating consistent growth.
- In FY2025, working capital increased 19.3% year-over-year.
- Ranks #48 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $823.5M | +19.3% |
| FY2024 | $690.6M | +50.2% |
| FY2023 | $459.8M | +15.6% |
| FY2022 | $397.8M | +113.3% |
| FY2021 | $186.5M | +56.8% |
| FY2020 | $118.9M | +508.1% |
| FY2019 | $19.6M | -66.6% |
| FY2018 | $58.6M | +22.2% |
| FY2017 | $48.0M | +182.3% |
| FY2016 | $17.0M | +83.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026